Summary:
- PreciseDx, a NYC-based company, raised $11M in funding for its breast cancer diagnostic, PreciseBreast, powered by its AI-platform OncoIntelligence.
- The funding round was led by Eventide Asset Management, Merck Global Health Innovation Fund, and Philips Ventures, among others.
- PreciseDx plans to use the funds for clinical data collection, commercial expansion, and the upcoming launch of its flagship product in 2026.
Article:
PreciseDx Secures $11M in Funding for Innovative Breast Cancer Diagnostic
PreciseDx, a New York City-based company, recently announced a successful funding round of $11 million for its groundbreaking breast cancer diagnostic, PreciseBreast. This innovative tool is driven by the company’s proprietary AI-platform, OncoIntelligence, which enhances the accuracy and efficiency of patient care planning.
Leading the investment round were prominent names in the healthcare and technology sectors, including Eventide Asset Management, Merck Global Health Innovation Fund, and Philips Ventures. Other contributors to the funding included Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors.
The primary focus of the funding will be to optimize ongoing clinical data collection, expand commercial operations, and prepare for the anticipated launch of PreciseDx’s flagship product in 2026. PreciseBreast is designed to streamline the care planning process for breast cancer patients by providing comprehensive insights into phenotype and grade, enabling the prediction of recurrence risk within hours.
Utilizing OncoIntelligence, the AI-platform combines seven morphologic features with four clinical factors to generate a single OncoIntelligence Score, ranging from 0 to 100. This innovative approach has been clinically validated in over 3,000 breast cancer cases, proving its ability to accurately stratify patients into risk-based cohorts for disease recurrence at six years.
With a strong focus on innovation and precision, PreciseDx is poised to revolutionize the landscape of breast cancer diagnostics and patient care. Stay tuned for updates on the company’s progress and the official launch of PreciseBreast in 2026.
Conclusion:
PreciseDx’s recent funding success highlights the growing interest and investment in AI-driven healthcare solutions, particularly in the field of breast cancer diagnostics. With its cutting-edge technology and strategic partnerships, the company is well-positioned to make a significant impact on patient care and outcomes in the years to come.
